McKesson strategy in US healthcare, shares track S&P 500 peers

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-22, 17:05.

McKesson (US58155Q1031) remains one of the largest drug distributors in the United States by revenue, with its shares trading on the NYSE and included in the S&P 500 healthcare cohort. Analysts on MarketBeat and other platforms continue to describe a predominantly Buy-oriented stance on the stock, with consensus price targets above the current quotation.

How McKesson positions in US healthcare

McKesson is a major wholesaler of branded, generic and specialty pharmaceuticals to retail pharmacies, hospitals and health systems across North America, with fiscal 2025 revenues in the hundreds of billions of dollars according to recent company filings. Its scale positions it as a key counterpart to manufacturers such as Johnson & Johnson and Pfizer as well as pharmacy chains like CVS Health and Walgreens Boots Alliance.

In addition to pharmaceutical distribution, McKesson also supplies medical-surgical products to physician offices, surgery centers and post-acute care facilities, reinforcing its role across the healthcare delivery chain. The company has also been active in specialty distribution and oncology-focused services, seeking to capture higher-margin segments than basic wholesale distribution.

Analyst views and sector comparison

On consensus platforms such as MarketBeat, McKesson currently carries a majority of Buy ratings, with only a small number of Hold recommendations and no widespread Sell calls reported. The average 12-month price target on the stock stands materially above the present market level, implying that analysts still see upside relative to recent trading ranges.

Compared with US healthcare peers in the S&P 500, including distributors like Cardinal Health and AmerisourceBergen (now Cencora), McKesson is often cited for its robust cash generation and shareholder return policies, including regular share repurchases. Sector commentators at outlets such as Reuters and other financial media have highlighted how large distributors have benefited from high drug volumes and a stable reimbursement environment over recent years.

What McKesson sells

McKesson’s core business is the distribution of prescription medicines, over-the-counter drugs and medical-surgical supplies to pharmacies, hospitals and other care providers, complemented by specialty services and technology solutions that help healthcare organizations manage inventories, reimbursement and clinical programs.

Where the shares trade today

The McKesson shares (US58155Q1031) most recently changed hands on the NYSE at around 750 US dollars according to intraday quote data, reflecting the company’s position among the higher-priced names in the S&P 500 healthcare segment.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data are based on sources considered reliable but cannot be guaranteed for accuracy or completeness. Investors should conduct their own research or consult a qualified advisor before making investment decisions.